Bibliography
- Moscatiello S, Di Luzio R, Sasdelli AS, Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opin Pharmacother 2011;13:2657-72
- Fraser A, Harris R, Sattar N, Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007;27:2729-35
- Athyros VG, Tziomalos K, Gossios TD, Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22
- Musso G, Cassader M, Gambino R. Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr Opin Lipidol 2011;22:489-96
- Foster T, Budoff MJ, Saab S, Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011;106:71-7
- Riley P, Al Bakir M, O'Donohue J, Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk. Cardiovasc Ther 2009;27:216-20
- Chalasani N, Aljadhey H, Kesterson J, Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92